Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab for treating TA-TMA. The stock fell nearly 20% in June and about 14% in October after the EMA's Committee for Medicinal Products for Human Use (CHMP) rejected the marketing authorization application twice. This investigation could impact investor confidence and legal outcomes for Omeros. Investors are advised to contact Pomerantz LLP for claims related to this matter.
Omeros Corporation faces a legal investigation following significant stock price drops tied to regulatory setbacks. For readers following the health sector, here is Pluang's market snapshot as of Oct 28, 2026 05:02 WIB: out of 150 priced health-sector US stocks, 90 rose and 60 fell. Notable movers include SELLAS Life Sciences Group Inc. (SLS) with a 7.32% gain at USD 12.17 and 10X Genomics Inc (TXG) up 6.92% at USD 78.01, despite a high sell order activity of 82%. Novavax Inc (NVAX) also gained 6.70% at USD 10.03 with a majority buy order activity of 74%.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Nokia Oyj is rated Buy due to strong demand in its Optical and IP Networks segments, driven by previous design wins and new contracts with hyperscalers. The company expects 25%-30% growth in these areas by 2027, supported by margin improvements from ...
Pomerantz LLP is investigating Concentrix Corporation and its executives for potential securities fraud following the company's lowered revenue and earnings forecasts and a significant $1.05 billion goodwill impairment. Concentrix's stock price dropp...
Icahn Enterprises L.P. announced it will present its third quarter 2026 financial results via a webcast on November 3, 2026, at 10:00 a.m. Eastern Time. The company operates across seven main sectors including Investment, Energy, Automotive, Food Pac...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
